Prostate Cancer Metastatic
Conditions
Keywords
Genomic sequencing, Transcriptome sequencing, Epigenetics, Metabonomics, Immunohistochemical, Multi-omics Study
Brief summary
The investigators plan to perform multi-omics technologies, including genomic, transcriptomic, epigenomic and proteomic methods, in patients with metastatic prostate cancer, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.
Detailed description
Prostate cancer is the commonest malignancy and the second leading cause of tumor-related death among males worldwide. Though patients with early stage prostate cancer can obtain satisfactory therapeutic efficacy from radical prostatectomy or radiotherapy, the prognosis of men with metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC), is still poor. Recent years have witnessed the rapid development of the high-throughput technologies, including genomic, transcriptomic, epigenomic and proteomic methods. These techniques are promising in uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets. In the current prospective study, the investigators plan to perform multi-omics technologies in patients with mPCa, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.
Interventions
None listed
Sponsors
West China Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathological confirmation of prostate cancer * Age: ≥40 years old * Bone or visceral metastatic disease confirmed by image examination. * Written informed consent
Exclusion criteria
* Patients harbouring other types of cancer besides prostate cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Genetic profiling results | From baseline (initial diagnosis of PCa), until study completion (48 months) | Mutation identified via whole-genome sequencing will be recored. |
| Transcriptional profiling results | From baseline (initial diagnosis of PCa), until study completion (48 months) | Determining the transcriptomic information of metastatic prostate cancer by performing whole transcriptome sequencing |
| Epigenomic profiling results | From baseline (initial diagnosis of PCa), until study completion (48 months) | Determining the epigenomic status of specific genes by performing DNA-methylation sequencing |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Protein expression results | From baseline (initial diagnosis of PCa), until study completion (48 months) | Determing the expression status of centain proteins by performing immunohistochemistry in prostate biopsy specimen |
Contacts
Primary ContactJinge Zhao, Dr.
Outcome results
None listed